Sarah Heeson Selected Research

ErbB Receptors (EGF Receptor)

9/2017

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sarah Heeson Research Topics

Disease

7	Breast Neoplasms (Breast Cancer) 01/2023 - 02/2015
1	Neoplasms (Cancer) 01/2023
1	Anaphylaxis (Anaphylactic Shock) 01/2023
1	Diarrhea 01/2023
1	Hypersensitivity (Allergy) 01/2023
1	Neutropenia 01/2021
1	Febrile Neutropenia 01/2021
1	Myocardial Infarction 01/2021
1	Disease Progression 09/2017

Drug/Important Bio-Agent (IBA)

7	Trastuzumab (Herceptin)FDA Link 01/2023 - 02/2015
7	pertuzumabIBA 01/2023 - 02/2015
2	human ERBB2 proteinIBA 01/2019 - 02/2015
1	Monoclonal AntibodiesIBA 01/2019
1	ErbB Receptors (EGF Receptor)IBA 09/2017
1	Capecitabine (Xeloda)FDA Link 09/2017
1	taxaneIBA 09/2017
1	Docetaxel (Taxotere)FDA Link 02/2015
1	Drug CombinationsIBA 02/2015

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 01/2023 - 02/2015
4	Therapeutics 01/2023 - 02/2015
2	Subcutaneous Injections 01/2023 - 01/2021
1	Intravenous Infusions 01/2021
1	Neoadjuvant Therapy 01/2021